NASDAQ:RETA - Reata Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $222.57
  • Forecasted Upside: 61.94 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.56 (-0.41%)

This chart shows the closing price for RETA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Reata Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RETA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RETA

Analyst Price Target is $222.57
▲ +61.94% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Reata Pharmaceuticals in the last 3 months. The average price target is $222.57, with a high forecast of $244.00 and a low forecast of $155.00. The average price target represents a 61.94% upside from the last price of $137.44.

This chart shows the closing price for RETA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Reata Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2021The Goldman Sachs GroupInitiated CoverageBuy$236.00High
5/20/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price TargetBuy$234.00 ➝ $244.00High
5/20/2021CitigroupBoost Price TargetPositive ➝ Buy$234.00 ➝ $244.00High
4/26/2021BarclaysInitiated CoverageOverweight$155.00High
11/25/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target$260.00 ➝ $234.00Low
11/25/2020Smith Barney CitigroupLower Price Target$260.00 ➝ $234.00Low
11/10/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$244.00 ➝ $260.00High
11/10/2020Cantor FitzgeraldBoost Price Target$169.00 ➝ $220.00High
11/10/2020Smith Barney CitigroupBoost Price Target$244.00 ➝ $260.00High
8/11/2020Cantor FitzgeraldLower Price Target$275.00 ➝ $169.00High
8/11/2020CitigroupLower Price TargetBuy$254.00 ➝ $244.00High
8/10/2020Stifel NicolausLower Price TargetBuy$280.00 ➝ $225.00Low
6/16/2020BTIG ResearchInitiated CoverageBuy$237.00Low
6/12/2020Robert W. BairdReiterated RatingBuy$268.00Low
5/18/2020Cantor FitzgeraldBoost Price TargetOverweight$270.00 ➝ $275.00Medium
4/17/2020Jefferies Financial GroupBoost Price TargetBuy$335.00 ➝ $348.00Low
3/31/2020Stifel NicolausLower Price TargetBuy$362.00 ➝ $315.00High
3/31/2020Robert W. BairdLower Price TargetOutperform$283.00 ➝ $268.00High
3/31/2020CitigroupLower Price TargetBuy$328.00 ➝ $254.00High
2/20/2020Stifel NicolausBoost Price TargetBuy$305.00 ➝ $362.00Medium
2/20/2020Robert W. BairdReiterated RatingOutperform$245.00 ➝ $283.00Low
2/20/2020Cantor FitzgeraldReiterated RatingOverweight$314.00 ➝ $320.00High
2/18/2020Jefferies Financial GroupReiterated RatingBuy$308.00 ➝ $333.00Medium
11/27/2019Cantor FitzgeraldBoost Price Target$250.00 ➝ $314.00Low
11/20/2019Cantor FitzgeraldReiterated RatingOverweight$250.00 ➝ $314.00Medium
11/14/2019Stifel NicolausReiterated RatingPositive ➝ Buy$210.00 ➝ $305.00Low
11/13/2019National SecuritiesDowngradeBuy ➝ NeutralMedium
11/12/2019CitigroupBoost Price TargetBuy$241.00 ➝ $328.00Medium
11/12/2019Robert W. BairdBoost Price TargetOutperform ➝ Positive$162.00 ➝ $245.00High
11/4/2019Cantor FitzgeraldBoost Price TargetOverweight$180.00 ➝ $250.00Medium
10/16/2019LADENBURG THALM/SH SHReiterated RatingBuy ➝ Positive$133.00 ➝ $239.00High
10/16/2019Stifel NicolausBoost Price TargetBuy$135.00 ➝ $210.00High
10/15/2019SVB LeerinkSet Price TargetBuy$230.00Medium
10/15/2019CitigroupBoost Price TargetBuy$194.00 ➝ $241.00High
10/15/2019Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$128.00 ➝ $254.00High
10/15/2019Robert W. BairdReiterated RatingOutperform$105.00 ➝ $162.00High
10/15/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$125.00 ➝ $180.00High
10/14/2019SVB LeerinkBoost Price TargetOutperform$139.00 ➝ $180.00High
9/26/2019CitigroupReiterated RatingBuyHigh
9/26/2019National SecuritiesInitiated CoverageBuy$130.00Medium
8/8/2019CitigroupBoost Price TargetBuy$190.00 ➝ $194.00Medium
5/31/2019CitigroupBoost Price TargetBuy$185.00 ➝ $190.00Low
2/28/2019Cantor FitzgeraldReiterated RatingBuy$100.00High
2/20/2019Cantor FitzgeraldSet Price TargetBuy$100.00Low
11/7/2018Cantor FitzgeraldSet Price TargetBuy$100.00High
10/1/2018Cantor FitzgeraldReiterated RatingBuy$100.00High
9/26/2018LADENBURG THALM/SH SHReiterated RatingBuy$133.00Low
9/25/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$116.00 ➝ $139.00Medium
8/23/2018Cantor FitzgeraldInitiated CoverageOverweight$90.00Low
8/9/2018SVB LeerinkBoost Price TargetOutperform$64.00 ➝ $116.00Low
7/24/2018CitigroupBoost Price TargetBuy ➝ Buy$76.00 ➝ $95.00High
7/24/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$47.00 ➝ $92.00High
4/9/2018CowenReiterated RatingHoldHigh
12/14/2017CowenReiterated RatingBuyMedium
11/14/2017CowenReiterated RatingBuyN/A
10/24/2017Robert W. BairdReiterated RatingBuy$47.00N/A
10/6/2017Jefferies Financial GroupReiterated RatingBuy$44.00N/A
9/13/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$43.00Medium
9/1/2017Robert W. BairdReiterated RatingBuy$47.00Medium
8/30/2017Jefferies Financial GroupInitiated CoverageBuy$44.00High
8/23/2017CitigroupReiterated RatingBuy$87.00 ➝ $78.00High
7/26/2017LADENBURG THALM/SH SHReiterated RatingBuy$55.00 ➝ $61.00High
7/25/2017Robert W. BairdReiterated RatingOutperform$43.00 ➝ $47.00High
7/25/2017Stifel NicolausReiterated RatingBuy$38.00 ➝ $50.00High
7/25/2017CitigroupReiterated RatingBuy ➝ Buy$39.00 ➝ $87.00High
7/24/2017Piper Jaffray CompaniesBoost Price TargetBuy$53.00 ➝ $60.00High
6/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$48.00 ➝ $53.00High
5/9/2017CitigroupBoost Price TargetBuy$32.00 ➝ $39.00Low
4/13/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$55.00Low
4/4/2017Piper Jaffray CompaniesReiterated RatingOverweight$48.00Medium
3/28/2017Piper Jaffray CompaniesReiterated RatingOverweight$48.00High
3/6/2017Piper Jaffray CompaniesReiterated RatingOverweight$48.00N/A
2/22/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$38.00N/A
1/24/2017Robert W. BairdInitiated CoverageOutperform$43.00N/A
12/1/2016CowenReiterated RatingBuyN/A
10/7/2016Piper Jaffray CompaniesSet Price TargetBuy$33.00N/A
(Data available from 6/21/2016 forward)
Reata Pharmaceuticals logo
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Read More

Today's Range

Now: $137.44
Low: $136.00
High: $140.06

50 Day Range

MA: $110.47
Low: $78.27
High: $146.01

52 Week Range

Now: $137.44
Low: $76.34
High: $186.82


306,842 shs

Average Volume

366,029 shs

Market Capitalization

$4.99 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Reata Pharmaceuticals?

The following equities research analysts have issued research reports on Reata Pharmaceuticals in the last year: Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Smith Barney Citigroup, Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for RETA.

What is the current price target for Reata Pharmaceuticals?

7 Wall Street analysts have set twelve-month price targets for Reata Pharmaceuticals in the last year. Their average twelve-month price target is $222.57, suggesting a possible upside of 61.3%. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the highest price target set, predicting RETA will reach $244.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $155.00 for Reata Pharmaceuticals in the next year.
View the latest price targets for RETA.

What is the current consensus analyst rating for Reata Pharmaceuticals?

Reata Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RETA will outperform the market and that investors should add to their positions of Reata Pharmaceuticals.
View the latest ratings for RETA.

What other companies compete with Reata Pharmaceuticals?

How do I contact Reata Pharmaceuticals' investor relations team?

Reata Pharmaceuticals' physical mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company's listed phone number is 972-865-2219 and its investor relations email address is [email protected] The official website for Reata Pharmaceuticals is